Ectopic CD137 expression facilitates the escape of hodgkin and reed-sternberg cells from immunosurveillance

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Pang, Wan Lu ^a   Ho, Weng Tong ^a   Schwarz, Herbert ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CD137; Classical hodgkin's lymphoma; Immune evasion; Reed sternberg cells

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; GAMMA INTERFERON;

ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTING CELL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVITY; CELL SELECTION; CELL SURFACE; CELL TRANSFER; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; CYTOKINE RELEASE; DOWN REGULATION; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; IMMUNE EVASION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REED STERNBERG CELL; T LYMPHOCYTE; TH1 CELL; TUMOR ESCAPE;

EID: 84886944229     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23441     Document Type: Article

References (10)

1. Küppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009; 1:491-6; PMID:20008234; http://dx.doi.org/10.1182/ asheducation-2009.1.491
2. Pawelec G. Tumour escape from the immune response. Cancer Immunol Immunother 2004; 53:843; PMID:15185008; http://dx.doi.org/10.1007/s00262-004-0531-y
3. Ho WT, Pang WL, Chong SM, Castella A, Al-Salam S, Tan TE, et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res 2013; 73:652-61; PMID:23204227; http://dx.doi. org/10.1158/0008-5472.CAN-12-3849
4. Anderson MW, Zhao S, Freud AG, Czerwinski DK, Kohrt H, Alizadeh AA, et al. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol 2012; 181:795-803; PMID:22901750; http://dx.doi.org/10.1016/j. ajpath.2012.05.015
5. Thum E, Shao Z, Schwarz H. CD137, implications in immunity and potential for therapy. Front Biosci 2009; 14:4173-88; PMID:19273343; http://dx.doi. org/10.2741/3521
6. Wang S, Lv J, Wang P, Yin X, Tan A, Chen Y. Recombinant human CD137L for cancer immunotherapy: effects of different fusions and linkers on its activity. Cancer Immunol Immunother 2011; 4:489-95; PMID:21968735
7. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162:5003-10; PMID:10202049
8. Shao Z, Sun F, Koh DR, Schwarz H. Characterisation of soluble murine CD137 and its association with systemic lupus. Mol Immunol 2008; 45:3990-9; PMID:18640726; http://dx.doi.org/10.1016/j. molimm.2008.05.028
9. Furtner M, Straub RH, Kruger S, Schwarz H. Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2005; 19:883-5; http://dx.doi. org/10.1038/sj.leu.2403675
10. Zhao S, Zhang H, Xing Y, Natkunam Y. CD137 Ligand Is expressed in primary and secondary lymphoid follicles and in B-cell lymphomas: diagnostic and therapeutic implications. Am J Surg Pathol 2013; 37:250-8; PMID:23095505; http://dx.doi. org/10.1097/PAS.0b013e318268c6ea